In the Review article published in the April issue of Nature Reviews Clinical Oncology there were errors in the clinical data presented in Tables 1 and 2. In addition, the primary end point of the adjuvant AVANT and NSABP-C-08 trials should have been disease-free survival (DFS) instead of progression-free survival (PFS). The errors have been corrected for the HTML and PDF versions of the article.
Additional information
The online version of the original article can be found at 10.1038/nrclinonc.2011.21
Rights and permissions
About this article
Cite this article
Ebos, J., Kerbel, R. Correction: Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 8, 316 (2011). https://doi.org/10.1038/nrclinonc.2011.74
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2011.74
This article is cited by
-
Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer
Cancer and Metastasis Reviews (2012)
-
The PCa Tumor Microenvironment
Cancer Microenvironment (2011)
